Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs
, , , , , e
20 ago 2020
INFORMAZIONI SU QUESTO ARTICOLO
Pubblicato online: 20 ago 2020
Pagine: 45 - 55
Ricevuto: 29 apr 2020
Accettato: 28 mag 2020
DOI: https://doi.org/10.2478/acm-2020-0006
Parole chiave
© 2020 K Prso et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Tuberculosis is an airborne infectious disease that remains a huge global health-related issue nowadays. Despite constant approvals of newly developed drugs, the use of first-line antituberculosis medicines seems reasonable in drug-susceptible